About
Gamida Cell is pioneering a diverse approach to cellular therapy that utilizes nicotinamide (NAM) to expand multiple cell types — including stem cells and natural killer (NK) cells — while maintaining their original phenotype and potency. When applied to umbilical cord blood–derived cells in the production of our investigational omidubicel product for allogeneic stem cell transplant, NAM-enabled cells have improved clinical measures such as engraftment time and infection rate, potentially leading to better outcomes for patients.
Gamida Cell has developed a reliable, scalable and GMP-compliant culture method for NAM expansion that yields highly functional NK cells. These cells have demonstrated ability to kill cancerous cells in both animal models and clinical trials, and are being developed in both unmodified and genetically engineered forms.
The company received FDA approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients.
Funding history · 10 rounds · $416.2M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Gamida Cell founded?
- Gamida Cell was founded in February 1998.
- What is Gamida Cell's primary focus in cellular therapy?
- Gamida Cell focuses on a diverse approach to cellular therapy using nicotinamide (NAM) to expand multiple cell types, including stem cells and natural killer (NK) cells, while maintaining their original phenotype and potency.
- What significant regulatory approval did Gamida Cell receive for its product Omisirge?
- In April 2023, Gamida Cell received FDA approval for Omisirge (omidubicel-onlv), an allogeneic cell therapy designed to reduce the risk of infection in blood cancer patients.
- What was a key operational development for Gamida Cell in March 2023?
- In March 2023, Gamida Cell announced a restructuring process supported by Highbridge Capital Management and laid off nearly one-fifth of its workforce.
- When did Gamida Cell complete its rolling Biologics License Application (BLA) submission to the FDA for Omidubicel?
- Gamida Cell completed its rolling Biologics License Application submission to the FDA for Omidubicel in June 2022.
- What was the outcome of Gamida Cell's acquisition in March 2024?
- In March 2024, Gamida Cell was acquired by Highbridge Capital Management and subsequently delisted from NASDAQ as Highbridge took full ownership.
- What was the total amount raised by Gamida Cell through various funding rounds?
- According to startupim data, Gamida Cell raised a total of $416,223,389 through its funding rounds. For full financing history, refer to startupim.
- Which investors participated in Gamida Cell's Series F round in June 2017?
- In June 2017, Gamida Cell raised $40,000,000 in its Series F round, with investors including Israel Biotech Fund and Novartis.
- What was the purpose of the strategic collaboration between Gamida Cell and Be The Match BioTherapies in January 2019?
- In January 2019, Gamida Cell and Be The Match BioTherapies announced a strategic collaboration to advance the treatment of blood cancers with NiCord.